Targeting the p53 signaling pathway in cancers: Molecular mechanisms and clinical studies
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Tumor suppressor p53 can transcriptionally activate downstream genes in response to stress, and then regulate the cell cycle, DNA repair, metabolism, angiogenesis, apoptosis, and other biological responses. p53 has seven functional domains and 12 splice isoforms, and different domains and subtypes play different roles. The activation and inactivation of p53 are finely regulated and are associated with phosphorylation/acetylation modification and ubiquitination modification, respectively. Abnormal activation of p53 is closely related to the occurrence and development of cancer. While targeted therapy of the p53 signaling pathway is still in its early stages and only a few drugs or treatments have entered clinical trials, the development of new drugs and ongoing clinical trials are expected to lead to the widespread use of p53 signaling‐targeted therapy in cancer treatment in the future. TRIAP1 is a novel p53 downstream inhibitor of apoptosis. TRIAP1 is the homolog of yeast mitochondrial intermembrane protein MDM35, which can play a tumor‐promoting role by blocking the mitochondria‐dependent apoptosis pathway. This work provides a systematic overview of recent basic research and clinical progress in the p53 signaling pathway and proposes that TRIAP1 is an important therapeutic target downstream of p53 signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
p21 in cancer: Intricate networks and multiple activities
Abbas, T., & Dutta, A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2657 · Cited by 2,712
Mitochondria and cell death: outer membrane permeabilization and beyond
Tait, S. W. G., & Green, D. R. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2952 · Cited by 2,593
Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation
Malta, T. M., Sokolov, A., Gentles, A. J., Burzykowski, T., Poisson, L., Weinstein, J. N., Kamińska, B., Huelsken, J., Omberg, L., Gevaert, O., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.034 · Cited by 2,180
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Jing, X., Yang, F., Shao, C., Wei, K., Xie, M., Shen, H., & Shu, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1089-9 · Cited by 2,054
TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis
Bensaad, K., Tsuruta, A., Selak, M. A., Vidal, M. N. C., Nakano, K., Bartrons, R., Gottlieb, E., & Vousden, K. H. (2006) · Cell · doi:10.1016/j.cell.2006.05.036 · Cited by 2,019
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619
Regulating the p53 pathway: in vitro hypotheses, in vivo veritas
Toledo, F., & Wahl, G. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc2012 · Cited by 1,286
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
The multiple mechanisms that regulate p53 activity and cell fate
Hafner, A., Bulyk, M. L., Jambhekar, A., & Lahav, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0110-x · Cited by 1,129
P53 in survival, death and metabolic health: a lifeguard with a licence to kill.
Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
p53 ubiquitination: Mdm2 and beyond
Brooks, C. L., & Gu, W. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.020 · Cited by 924
p53 Sites Acetylated In Vitro by PCAF and p300 Are Acetylated In Vivo in Response to DNA Damage
Liu, L., Scolnick, D. M., Trievel, R. C., Zhang, H. B., Marmorstein, R., Halazonetis, T. D., & Berger, S. L. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.2.1202 · Cited by 776
Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects
Hartmann, J., Haap, M., Kopp, H.-G., & Lipp, H.-P. (2009) · Current Drug Metabolism · doi:10.2174/138920009788897975 · Cited by 630
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
p53: traffic cop at the crossroads of DNA repair and recombination
Sengupta, S., & Harris, C. C. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1546 · Cited by 544
Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes
Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02341 · Cited by 465
Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development
Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000657 · Cited by 395
p53 modifications: exquisite decorations of the powerful guardian
Liu, Y., Tavana, O., & Gu, W. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz060 · Cited by 392
DNA Damage-Induced Acetylation of Lysine 3016 of ATM Activates ATM Kinase Activity
Sun, Y., Xu, Y., Roy, K., & Price, B. D. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01382-07 · Cited by 319
Li, Y., Yang, J., Aguilar, A., McEachern, D., Przybranowski, S., Liu, L., Yang, C.-Y., Wang, M., Han, X., & Wang, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00909 · Cited by 312
Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy
Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z., & Hu, W. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.030 · Cited by 308
Monoubiquitylation promotes mitochondrial p53 translocation
Marchenko, N. D., Wolff, S., Erster, S., Becker, K., & Moll, U. M. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601560 · Cited by 286
Cluzeau, T., Sebert, M., Rahmé, R., Cuzzubbo, S., Lehmann-Che, J., Madelaine, I., Peterlin, P., Bève, B., Attalah, H., Chermat, F., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02342 · Cited by 279
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
Carvajal, L. A., Neriah, D. B., Senecal, A., Benard, L., Thiruthuvanathan, V., Yatsenko, T., Narayanagari, S.-R., Wheat, J. C., Todorova, T. I., Mitchell, K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao3003 · Cited by 249
Schleich, K., Warnken, U., Fricker, N., Öztürk, S., Richter, P., Kammerer, K., Schnölzer, M., Krammer, P. H., & Lavrik, I. N. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.05.006 · Cited by 198
p53 engages the cGAS/STING cytosolic DNA sensing pathway for tumor suppression
Ghosh, M., Saha, S., Li, J., Montrose, D. C., & Martinez, L. A. (2023) · Molecular Cell · doi:10.1016/j.molcel.2022.12.023 · Cited by 166
Canon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0710 · Cited by 152
Mishra, A., Tamari, R., DeZern, A. E., Byrne, M. T., Gooptu, M., Chen, Y.-B., Deeg, H. J., Sallman, D., Gallacher, P., Wennborg, A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.00181 · Cited by 146
DNA triplet repeat expansion and mismatch repair
Iyer, R. R., Pluciennik, A., Napierala, M., & Wells, R. D. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034010 · Cited by 130
Chk1 and Claspin potentiate PCNA ubiquitination
Yang, X. H., Shiotani, B., Classon, M., & Zou, L. (2008) · Genes & Development · doi:10.1101/gad.1632808 · Cited by 111
TSC1/TSC2 signaling in the CNS
Han, J. M., & Sahin, M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.02.001 · Cited by 105
p53CSV, a Novel p53-Inducible Gene Involved in the p53-Dependent Cell-Survival Pathway
Park, W.-R., & Nakamura, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3339 · Cited by 72
Chapeau, E. A., Gembarska, A., Durand, E. Y., Mandon, E., Estadieu, C., Romanet, V., Wiesmann, M., Tiedt, R., Lehar, J., de Weck, A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620262114 · Cited by 64
Deng, S., Vlatkovic, T., Li, M., Zhan, T., Veldwijk, M. R., & Herskind, C. (2022) · Cancers · doi:10.3390/cancers14194874 · Cited by 62
Hoffman-Luca, C. G., Ziazadeh, D., McEachern, D., Zhao, Y., Sun, W., Debussche, L., & Wang, S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2506 · Cited by 52
Insights into regulators of p53 acetylation
Nagasaka, M., Miyajima, C., Aoki, H., Aoyama, M., Morishita, D., Inoue, Y., & Hayashi, H. (2022) · Cells · doi:10.3390/cells11233825 · Cited by 45
Structural and Functional Comparison of the RING Domains of Two p53 E3 Ligases, Mdm2 and Pirh2
Shloush, J., Vlassov, J. E., Engson, I., Duan, S., Saridakis, V., Dhe-paganon, S., Raught, B., Sheng, Y., & Arrowsmith, C. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.157669 · Cited by 42
Self-citationVerstovsek, S., Al-Ali, H. K., Mascarenhas, J., Perkins, A., Vannucchi, A. M., Mohan, S. R., Scott, B. L., Woszczyk, D., Koschmieder, S., García-Delgado, R., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0901 · Cited by 41
Research works printed but not linked: 376
- 10.3390/cancers14235733 · DOI
- 10.1016/0016-5085(94)90431-6 · DOI
- 10.1016/j.tcb.2009.10.002 · DOI · Paper page
- 10.1016/j.tibs.2015.04.007 · DOI
- 10.1016/j.tig.2022.02.010 · DOI · Paper page
- 10.1038/nrc1954 · DOI · Paper page
- 10.1007/s00018-022-04505-w · DOI
- 10.4161/cc.4.9.1981 · DOI · Paper page
- 10.3389/fcell.2022.818744 · DOI
- 10.1038/sj.emboj.7600608 · DOI · Paper page
- 10.1200/JCO.2005.05.019 · DOI · Paper page
- 10.1016/j.celrep.2019.07.001 · DOI · Paper page
- 10.3389/fonc.2022.1006959 · DOI
- 10.1016/j.cell.2022.10.004 · DOI · Paper page
- 10.1080/15548627.2021.2008752 · DOI
- 10.1016/j.molcel.2021.08.023 · DOI
- 10.1021/jacs.1c06169 · DOI
- 10.1186/s13045-021-01169-0 · DOI · Paper page
- 10.1186/s40164-022-00317-7 · DOI · Paper page
- 10.1016/j.lfs.2022.121361 · DOI
- 10.1038/s41467-023-36755-y · DOI
- 10.1002/hep.30807 · DOI
- 10.1200/JCO.2002.20.4.883 · DOI
- 10.1016/j.cbpa.2022.102230 · DOI
- 10.3390/ijms232113287 · DOI
- 10.3389/fonc.2022.1000677 · DOI
- 10.1158/2159-8290.CD-22-1131 · DOI
- 10.1126/scitranslmed.aay2163 · DOI
- 10.1097/JTO.0000000000000584 · DOI
- 10.1093/jnci/djp376 · DOI
- 10.1093/jmcb/mjaa040 · DOI · Paper page
- 10.1038/s41573-022-00571-8 · DOI · Paper page
- Li W, 2022, Early biomarkers associated with P53 signaling for acute radiation injury, Life (Basel), 12
- 10.3389/fgene.2022.855355 · doi:10.3389/fgene.2022.855355
- 10.1159/000501633 · DOI
- 10.1371/journal.pgen.1000129 · DOI · Paper page
- 10.1158/2159-8290.CD-22-0332 · DOI · Paper page
- 10.3390/ijms21010013 · DOI
- 10.3390/biom12111558 · DOI
- 10.2174/138920107783018444 · DOI · Paper page
- 10.1038/sj.cdd.4401914 · DOI · Paper page
- 10.1038/s41419-022-05349-9 · DOI
- 10.1038/onc.2010.266 · DOI
- 10.4161/cc.8.8.8251 · DOI · Paper page
- 10.1126/sciadv.abi6684 · DOI
- 10.3390/cancers12113422 · DOI
- 10.1016/j.febslet.2010.10.005 · DOI · Paper page
- 10.1038/cdd.2014.73 · DOI
- 10.1038/ncomms5706 · DOI
- 10.1038/s41375-022-01634-w · DOI · Paper page
- 10.1038/s41467-021-20928-8 · DOI
- 10.1021/acs.accounts.7b00473 · DOI
- 10.1016/j.molcel.2019.03.032 · DOI
- 10.3390/cancers11081079 · DOI
- 10.21037/atm.2020.02.142 · DOI
- 10.1016/j.drup.2019.100671 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.113.005224 · DOI
- 10.1093/nar/gkab222 · DOI
- 10.1038/s41556-020-0559-z · DOI · Paper page
- 10.1101/cshperspect.a000950 · DOI · Paper page
- 10.1101/cshperspect.a026047 · DOI · Paper page
- 10.1038/s41417-022-00513-x · DOI
- 10.1182/blood.2020009997 · DOI
- 10.1016/j.molcel.2020.07.021 · DOI
- 10.1016/j.ccr.2006.10.012 · DOI
- 10.1186/1476-4598-12-35 · DOI
- 10.1038/s41467-022-35089-5 · DOI
- 10.1126/scisignal.aao4170 · DOI · Paper page
- 10.1038/onc.2009.71 · DOI · Paper page
- 10.1016/S0092-8674(00)00073-8 · DOI · Paper page
- 10.1038/onc.2010.115 · DOI
- 10.1186/s13046-022-02288-3 · DOI
- 10.18632/oncotarget.9046 · doi:10.18632/oncotarget.9046
- 10.1136/gutjnl-2020-321386 · DOI
- 10.1038/s41417-020-0175-x · DOI
- 10.7150/thno.21963 · DOI
- 10.1158/0008-5472.CAN-20-1804 · DOI
- 10.1074/jbc.M210696200 · DOI · Paper page
- Scolnick DM, 1997, CREB‐binding protein and p300/CBP‐associated factor are transcriptional coactivators of the p53 tumor suppressor protein, Cancer Res, 57, 3693
- 10.1158/1078-0432.CCR-05-1230 · DOI
- 10.1016/j.arr.2018.02.004 · DOI · Paper page
- 10.1016/j.canlet.2015.04.015 · DOI
- 10.1016/S0092-8674(00)80521-8 · DOI · Paper page
- 10.1016/j.celrep.2016.09.022 · DOI · Paper page
- 10.1016/j.bbrc.2014.08.122 · DOI
- 10.1371/journal.pone.0115401 · DOI · Paper page
- 10.1158/0008-5472.CAN-18-2357 · DOI
- 10.3390/ijms222413198 · DOI
- 10.1007/2789_2008_105 · DOI
- 10.1038/nature02514 · DOI · Paper page
- 10.1038/nsmb.1521 · DOI · Paper page
- 10.1038/emboj.2011.125 · DOI
- 10.1016/j.omtm.2021.01.015 · DOI
- 10.1016/j.bbrc.2007.11.176 · doi:10.1016/j.bbrc.2007.11.176
- 10.1021/acs.chemrev.6b00737 · DOI · Paper page
- 10.1593/neo.06439 · DOI
- 10.1007/s12026-022-09334-4 · doi:10.1007/s12026-022-09334-4
- 10.1038/s41467-019-09471-9 · DOI
- 10.1016/j.molcel.2006.05.016 · DOI · Paper page
- 10.3390/cancers14112806 · DOI
- 10.1002/anie.202215704 · DOI
- 10.1002/advs.202206169 · DOI
- 10.1016/S1470-2045(22)00633-7 · DOI
- 10.4161/cc.21235 · DOI
- 10.1093/nar/gkt012 · DOI · Paper page
- 10.1016/j.cell.2007.03.048 · DOI · Paper page
- 10.3390/ijms23158187 · DOI
- 10.1016/j.tig.2020.12.005 · DOI · Paper page
- 10.1016/j.arr.2009.04.005 · DOI
- 10.1016/j.drup.2022.100805 · DOI
- 10.1146/annurev-biochem-052521-035949 · DOI
- 10.7150/jca.81027 · DOI
- 10.1371/journal.pgen.1010012 · DOI
- 10.1093/narcan/zcab026 · DOI
- 10.1038/s41418-022-00962-9 · DOI
- 10.1038/s41589-023-01267-9 · DOI
- 10.1038/s41586-019-1678-1 · DOI · Paper page
- 10.1038/s41467-018-05567-w · DOI · Paper page
- 10.15252/embj.201797833 · DOI
- 10.1016/j.ijbiomac.2023.123180 · DOI
- 10.1016/j.cbpa.2022.102259 · DOI
- 10.1016/j.bbrc.2019.06.152 · DOI
- 10.1016/j.bbrc.2021.01.074 · DOI
- 10.7150/ijbs.69784 · DOI
- 10.1038/leu.2016.293 · DOI
- 10.1007/s11033-010-0099-x · DOI
- 10.1038/s41598-017-17973-z · DOI
- 10.1158/0008-5472.CAN-14-2430 · DOI
- 10.1016/S0378-1119(01)00543-1 · DOI
- 10.1128/MCB.00821-08 · DOI
- 10.1016/j.tig.2021.03.001 · DOI
- 10.1016/j.tig.2020.01.001 · DOI
- 10.3390/cancers13143415 · DOI
- 10.1016/j.yexcr.2006.01.020 · DOI
- 10.1128/MMBR.64.2.435-459.2000 · DOI · Paper page
- 10.1080/15548627.2022.2062112 · DOI · Paper page
- 10.1016/j.ejmech.2022.115020 · DOI
- 10.1182/blood.2019003439 · DOI
- 10.1016/j.semcdb.2022.04.001 · DOI
- 10.1016/j.molmed.2013.07.005 · DOI · Paper page
- 10.1146/annurev-biochem-082411-113907 · DOI · Paper page
- 10.3390/cells7050036 · DOI
- 10.3892/ijo.2014.2377 · DOI
- 10.1016/S0968-0004(02)02166-7 · DOI · Paper page
- 10.1016/j.febslet.2010.09.019 · DOI
- 10.26508/lsa.202201472 · DOI
- 10.18632/oncotarget.2081 · DOI
- 10.1007/s00280-019-03923-1 · DOI
- 10.1016/j.febslet.2010.06.027 · DOI
- 10.1002/hep.24329 · DOI
- 10.1038/sj.emboj.7600836 · DOI
- 10.1016/j.molcel.2013.05.006 · DOI
- 10.1038/onc.2009.314 · DOI
- 10.1038/cdd.2010.168 · DOI
- 10.1161/01.RES.0000253975.76198.ff · DOI · Paper page
- 10.1161/CIRCULATIONAHA.113.002434 · DOI · Paper page
- 10.1182/blood-2005-08-3273 · DOI · Paper page
- 10.1016/j.phrs.2023.106696 · DOI
- 10.1021/acs.jmedchem.1c00940 · DOI · Paper page
- 10.1007/s12032-022-01929-z · DOI
- 10.1073/pnas.0908027106 · DOI · Paper page
- 10.1093/hmg/ddh165 · DOI
- 10.1186/1471-2121-3-30 · DOI
- 10.1016/j.jep.2022.116046 · DOI
- Jiang W, 2020, Hsa‐miR‐217 inhibits the proliferation, migration, and invasion in non‐small cell lung cancer cells via targeting SIRT1 and P53/KAI1 signaling, Balkan Med J, 37, 208
- 10.1371/journal.pone.0016427 · DOI
- 10.1038/oncsis.2017.12 · DOI
- 10.1080/15384101.2016.1261767 · DOI
- 10.18632/aging.203459 · doi:10.18632/aging.203459
- 10.1080/08830185.2020.1795153 · DOI
- Wu CE, 2022, In vitro and in vivo study of GSK2830371 and RG7388 combination in liver adenocarcinoma, Am J Cancer Res, 12, 4399
- 10.1016/j.ccr.2007.08.033 · DOI · Paper page
- 10.1016/j.tcb.2020.12.011 · DOI · Paper page
- 10.1016/j.ccell.2018.12.012 · DOI · Paper page
- 10.1038/s41568-022-00535-5 · DOI · Paper page
- 10.1002/smll.202205166 · DOI
- 10.3390/cancers15020551 · DOI
- 10.1007/s12282-018-0913-1 · DOI
- 10.1016/j.ando.2019.04.010 · DOI
- 10.1158/0008-5472.CAN-04-3995 · DOI · Paper page
- 10.1023/A:1023725029589 · DOI · Paper page
- 10.1200/JCO.2002.09.147 · DOI
- 10.1200/JCO.1999.17.10.3150 · doi:10.1200/jco.1999.17.10.3150
- 10.3389/fcell.2022.1012179 · doi:10.3389/fcell.2022.1012179
- 10.3390/ijms21030870 · DOI
- 10.3390/ijms21103670 · DOI
- 10.1007/978-1-4614-8289-5_6 · DOI
- 10.1016/j.tig.2019.11.005 · DOI · Paper page
- 10.1111/eos.12685 · DOI
- 10.21873/anticanres.15510 · DOI
- Aljabal G, 2020, 14‐3‐3sigma and its modulators in cancer, Pharmaceuticals (Basel), 13, 10.3390/ph13120441 · DOI
- 10.1111/pin.13147 · DOI
- 10.1158/1078-0432.CCR-03-0510 · DOI
- 10.1016/j.cca.2020.09.009 · DOI
- 10.1128/MCB.23.20.7096-7107.2003 · DOI · Paper page
- 10.1158/2159-8290.CD-22-0244 · DOI
- 10.1002/adma.202207384 · DOI
- 10.1016/j.bbcan.2005.11.002 · DOI · Paper page
- 10.1016/j.cca.2013.05.002 · DOI · Paper page
- 10.1016/j.semcancer.2022.09.006 · DOI
200 of 376 shown
Metadata
- Authors
- Shen, J., Wang, Q., Mao, Y., Gao, W., & Duan, S.
- Venue
- MedComm
- Publisher
- Wiley
- Published
- 2023-05-28
- Volume
- 4
- Issue
- 3
- ISSN
- 2688-2663
- Cited by
- 62
- References
- 44
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.